A 15 year old girl was admitted with absence of menstruation and increase growth of facial and body hair for two years along with change of voice for six months. With these complaint, tablet progesterone was advised but there was no withdrawal bleeding. On examination she had hirsuitism. 
Introduction
Adrenocortical carcinoma is uncommon and extremely rare in children. The majority of cases present with a combination of clinical features of Cushing's syndrome and hyperandrogenism with or without pulmonary metastasis. [1] [2] [3] Hypertension may not be always present. 4 Diagnosis depends on clinical manifestations, demonstration of elevated hormone levels and localization of tumour(s). Surgical removal of tumor often normalizes the features but medical management is sometimes required. 1,3
Fig.-1: Hirsuitism and frontal balding in the study case
Case Report A 15 years girl was admitted with absence of menstruation and increase growth of facial and body hair for 2 years along with change of voice for 6 months. She attained her menarche 3 years back at the age of 12 years. Her menstrual cycle was irregular since beginning. She had only 3 cycles in 1st year after menarche. Later on she became amenorrhic. She visited a gynecologist who advised tab. progesterone but there was no withdrawal bleeding. After getting high S. testosterone level (4.0 pmol/l) and left adrenal mass in USG, she was referred to Endocrinology unit for evaluation and management. She did not have any history of severe illness in her childhood. She was delivered by normal vaginal delivery and her perinatal period was uneventful. She is nondiabetic and normotensive. She did not have any significant positive family history. On general examination hirsuitism was present. Her breast development was normal, external genitalia and pubic hair is of normal female type. There was mild clitoromegaly.
Subsequent laboratory investigations showed normal routine tests reports with normal X-ray chest and E.C.G. Hormone levels were: S.Testosterone 4.19 pmol/l(0.2-0.9), DHEA-9.8 pmol/l (1.3-9.8), 17 hydroxyprogesterone level 1.3 9 (< 80 ng/dL), TSH -3.69µ IU/l (0.4-5.03), FT4-16.16 ng/ml (9.0-23.0), Basal Cortisol-550 ng/ml. that left adrenal gland was enlarged 7cm×6cm, firm and there was no adhesion to adjacent structures and any peritoneal seedling or regional lymphadenopathy. Histopathology revealed left adrenocortical carcinoma.
One month after surgery her S.testosterone level was 0.15 pmol/l, LH-2.28 mIU/l, FSH-2.11mIU/l. Her menstruation started spontaneously one month following surgery. She noticed gradual reduction of body hairs. She was discharged from hospital with advice to come for regular follow up.
Discussion
Adrenocortical carcinoma is a rare tumor and only limited information is available about its natural history and the effects of therapy. Radical surgical excision is the treatment of choice for patients with localized malignancy and remains the only method by which longterm disease-free survival may be achieved. Overall 5-years survival after resection of tumor is approximately 40%. Approximately 60% of patients present with symptoms related to excessive hormone secretion but hormone testing reveals that 60% to 80% of tumors are functioning. 5, 6 The most common sites of metastases are the peritoneum, lung, liver, and bone. Palliation of metastatic functioning tumors may be achieved by resection of both the primary tumor and metastatic lesions. Unresectable or widely disseminated tumors may be palliated by antihormonal therapy with mitotane, systemic chemotherapy, or (for localized lesions) radiation therapy. Retrospective studies have identified two Because of the rarity of adrenocortical carcinoma, after operation survival rate and the prognosis is not well known. The French Association of Endocrine Surgery evaluated these factors in all patients treated during a 12-year period by its members. 8 Multivariate analysis showed that better prognosis occurred in patients younger than 35 years of age (p=0.01) and in patients with androgen-secreting tumors, precursor-secreting tumors, or nonsecreting tumors (p=0.003). Mitotane improved the survival rate only in patients with metastases who received it after operation .This is a case is a rare endocrine case in perspective of its incidence and its age of presentation.
